Presacor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Presacor

Presacor is a specialized pharmaceutical preparation for ophthalmic use, containing the active compound Prednisolone Acetate, which is a powerful synthetic anti-inflammatory agent. This medicine is defined by its steroid structure and its localized action on the inflammatory response.


Quick Facts: Presacor (Prednisolone Acetate)

Property Description
Active Ingredient Prednisolone Acetate
Form Ophthalmic suspension (eye drops)
Pharmacological Class Synthetic Glucocorticoid (Corticosteroid)
Common Use Control of localized inflammation in the eye
Origin Synthetic steroid derivative

Presacor: What Type of Medicine is It? (Identity and Class)

Presacor is specifically categorized as a synthetic glucocorticoid, belonging to the broader corticosteroid class of drugs. The active ingredient, Prednisolone Acetate, is a chemical derivative of the naturally occurring stress hormone cortisol, manufactured to provide a significantly greater anti-inflammatory potency than its natural analogue. This potency difference is a characteristic of the treatment of acute inflammation, where rapid suppression of the immune response is necessary. This classification confirms the drug's fundamental role as a powerful anti-inflammatory agent.

Composition and Physical Form (Origin and Delivery)

The active substance is Prednisolone Acetate, which is entirely synthetic in origin. Presacor is typically formulated as a sterile ophthalmic suspension or eye drops and is intended strictly for topical ophthalmic use. The suspension form is a key feature, as it utilizes a microfine particle size for the active ingredient, which allows for the controlled delivery and temporary adherence of the steroid to the ocular surface. This localized administration is a crucial differentiating factor, ensuring the anti-inflammatory action is concentrated on the eye rather than requiring systemic absorption.

General Purpose: How Presacor Addresses Inflammation

The general therapeutic purpose of Presacor is to control localized inflammation within the eye by acting as an immunosuppressive agent. The medication functions by intervening in the biological cascade that causes inflammation and the associated cellular signaling pathways. This targeted action results in the general relief of swelling, redness, and itching, fulfilling its primary role in suppressing the underlying immune mechanisms responsible for the inflammatory signs. Corticosteroids are utilized to reduce inflammation by modulating cell function.

Regulatory References

  1. MedlinePlus, Prednisolone Ophthalmic Drug Information

What side effects are possible with Presacor?

Possible Side Effects and Safety Information

Presacor, a corticosteroid, is associated with a range of possible side effects across multiple organ systems. These effects are often dependent on the dose and duration of therapy.

Serious and Clinically Significant Adverse Reactions

The most serious documented safety concerns relate to immunosuppression, which increases the risk of new infection and can mask the signs of existing or latent infections. Other major safety risks include adrenal suppression (secondary adrenocortical and pituitary unresponsiveness), gastrointestinal perforation (particularly in patients with certain GI disorders), decreases in bone density leading to osteoporosis and fractures, and serious ophthalmic effects such as posterior subcapsular cataracts and glaucoma (increased intraocular pressure).

Common Adverse Reactions and Organ System Effects

Commonly reported adverse reactions include fluid retention, elevation in blood pressure, alterations in glucose tolerance, increased appetite and weight gain, and behavioral and mood changes (e.g., insomnia, euphoria, mood swings, or severe depression/psychosis).

Adverse effects are documented across several System-Organ Classes, including:

  • Endocrine and Metabolic: Development of Cushingoid state, hyperglycemia (diabetes manifestation or exacerbation), menstrual irregularities.
  • Musculoskeletal: Loss of muscle mass, muscle weakness, aseptic necrosis of bone heads, pathologic fracture.
  • Cardiovascular/Renal: Salt and water retention, hypokalemia.
  • Dermatologic: Thin fragile skin, impaired wound healing, acne, striae.

Safety Restrictions and Monitoring

Presacor is contraindicated in patients with active systemic fungal infections, cerebral malaria, and specific viral or bacterial infections.

Special caution is warranted in patients with pre-existing conditions like diabetes, glaucoma, heart failure, peptic ulcer disease, or hypertension. Prolonged use requires routine monitoring of blood pressure, serum sodium and potassium levels, intraocular pressure, and bone density.

Overdose and Emergency Response

The official regulatory profile for Presacor overdose is defined by its localized ophthalmic route. Regulatory documents state that acute overdosage resulting from topical ocular administration is unlikely to cause immediate systemic problems and will not ordinarily cause acute systemic symptoms. The regulatory information for this formulation confirms that acute systemic effects are generally not expected with topical use.

Urgent medical attention is required primarily in the circumstance of accidental oral ingestion of the suspension. If the medication is swallowed, official regulatory guidance mandates to seek immediate medical attention or call the Poison Help line. For accidental ingestion, the initial procedural step described in labeling is to drink fluids to dilute the product. General management of overexposure is typically limited to symptomatic and supportive treatment, as no specific antidote is known for prednisolone acetate overdose.

A separate systemic risk noted in regulatory documents pertains to the potential for systemic hypercorticoidism, such as adrenal suppression or Cushing's syndrome. This is not an acute overdose manifestation, but rather a documented risk for infants and young children who receive prolonged, frequent, or excessive administration of the topical steroid.

Therapeutic Uses of Presacor

What Presacor Treats: Main Uses and Benefits

Presacor is commonly used to help manage symptoms related to heightened inflammatory or irritative states in the eye. The medication is generally applied in contexts where additional symptomatic support is needed, focusing on conditions presenting with localized discomfort. The medication is indicated for addressing steroid-responsive inflammation affecting the external ocular structures and anterior segment.

The medication is typically relevant for easing symptom clusters that may become intense or disruptive, including pronounced swelling, widespread redness, and challenging sensations like burning and persistent itching. Clinically, it is used across conditions characterized by periods of heightened symptoms, such as non-infectious keratitis, iritis, uveitis, and inflammatory responses following injuries or eye surgeries (like cataract removal). It provides support that helps ease the overall symptom burden, contributing to improved comfort during symptomatic periods.

Quick Fact: Relief for Ocular Discomfort

Symptom Focus Application Context Primary Benefit
Swelling & Redness Acute inflammatory episodes Helps stabilize physical signs
Itching & Burning Allergic or irritative states Contributes to improved comfort

Regulatory References

  1. DailyMed NIH overview of Prednisolone Acetate

Eligibility and Restrictions for Use

Who Can and Cannot Use Presacor? (Eligibility Rules)

The official population eligibility for Presacor (Prednisolone Acetate ophthalmic suspension) is strictly governed by regulatory documentation, which defines absolute prohibitions and necessary cautious use.

Absolute Contraindications (Must Not Use)

Presacor is contraindicated and must not be used by individuals with:

  • Known or suspected hypersensitivity to the active ingredient or any component of the formulation.
  • Most active viral diseases of the cornea and conjunctiva (e.g., epithelial herpes simplex keratitis).
  • Mycobacterial or fungal diseases of the ocular structures.
  • Acute untreated purulent ocular infections.

Conditional Use and Special Caution

Use is restricted and requires specific medical monitoring in certain populations and conditions:

  • Patients with Glaucoma: Requires caution and frequent monitoring of intraocular pressure.
  • History of Ocular Herpes Simplex: Requires great caution due to the risk of viral reactivation.
  • Soft Contact Lens Wearers: Lenses must be removed before use and reinserted 15 minutes after administration.
  • Pregnancy and Lactation: Use during pregnancy is conditional, only if the potential benefit justifies the risk; use is generally not recommended while breastfeeding.
  • Pediatric Patients: Safety and effectiveness have not been established in the general pediatric population.

What should I know about interactions with other medicines?

Presacor (Amlodipine) Interactions with other medicines and products

Presacor is metabolized by the CYP3A4 enzyme in the liver, meaning its concentration in the blood can be affected by other medicines that interact with this enzyme system. These interactions can be classified as clinically significant, requiring monitoring or dose adjustment.

Interacting Product Category Effect on Presacor Clinical Relevance
Strong/Moderate CYP3A4 Inhibitors Increases Presacor exposure/levels, increasing risk of side effects (e.g., hypotension, edema). Clinically significant, often requires Presacor dose reduction and close monitoring.
CYP3A4 Inducers Decreases Presacor exposure/levels, potentially reducing its therapeutic effect. Clinically significant, may require Presacor dose increase and blood pressure monitoring.
Other Anti-Hypertensives Additive blood pressure-lowering effect. Requires blood pressure monitoring to manage potential excessive hypotension.

Specific interacting medicinal products and substances explicitly noted in regulatory documents include strong CYP3A4 inhibitors such as certain antifungals (e.g., ketoconazole, itraconazole) and macrolide antibiotics (e.g., clarithromycin, erythromycin). CYP3A4 inducers, such as rifampicin and St. John's Wort, may lead to sub-therapeutic levels of Presacor. Presacor also increases the exposure of some statins, such as simvastatin, requiring a restriction on the maximum permissible daily dose of simvastatin when co-administered. Due to its vasodilatory effect, co-administration with other medicines that lower blood pressure, including beta-blockers or diuretics, may result in an enhanced anti-hypertensive effect, leading to potential dizziness or low blood pressure.

Mechanism of Action

Gene-Level Control of Inflammation

The primary action of Presacor begins when its active form, prednisolone, acts as an agonist at the intracellular Glucocorticoid Receptor (GR) in target cells. This complex moves to the cell nucleus to perform transrepression, which physically blocks the genes that code for key pro-inflammatory transcription factors like NF-κB. This molecular intervention effectively switches off the cell's ability to manufacture a vast array of inflammatory mediators, resulting in a profound physiological dampening of the localized immune response.


Blockade of the Mediator Production Cascade

The drug simultaneously initiates a cascading effect by inducing anti-inflammatory proteins that inhibit the enzyme Phospholipase A2 (PLA2). By blocking PLA2, the release of arachidonic acid—the necessary precursor—is prevented, thereby stopping the synthesis of powerful inflammatory agents like prostaglandins and leukotrienes. This dual molecular mechanism suppresses both the generation of inflammatory signals and the cellular infiltration they would normally cause, resulting in the physiological limitation of local capillary permeability and localized fluid accumulation in the ocular tissue.

Dosage and Administration Information

How to use Presacor — Administration Guidelines

Presacor is an oral medication. The instructions for use, as established in standard protocols, define the procedural steps for its use.

Administration Details

Guideline Instruction
Route of Administration Oral
Dosing Rule Take one (1) Presacor tablet daily.
Frequency and Timing Once daily, at approximately the same time each day.
Preparation None. Swallow the tablet whole. Do not chew, crush, or break the tablet.
Timing with Meals May be taken with or without food.
Age-Group Rule Approved for use in adults (18 years and older).

Procedural Instructions

Missed Dose: If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Patients should then return to their regular dosing schedule and must not take two doses to make up for the missed one.

Step Sequence:

  1. Verify one Presacor tablet for the daily dose.
  2. Swallow the tablet whole with a sufficient amount of water.
  3. Administer the dose once daily, at a consistent time.

These guidelines focus strictly on the physical procedure of use to ensure the medication is administered correctly.

Recent Clinical Evidence

Evidence for Use in Managing Post-Surgical Ocular Inflammation

The available research for this medicine in a post-surgical setting, such as following cataract removal, consists primarily of Randomized Controlled Trials (RCTs) and summaries from Systematic Reviews. These studies were designed to monitor measures related to inflammatory or irritative states. Research examined the clearance of inflammation within the eye's anterior chamber, typically measured by quantifying cells and flare. Follow-up durations were limited, meaning long-term outcomes are not fully established beyond the immediate recovery phase.

Evidence for Use in General Steroid-Responsive Inflammatory Conditions

The evidence base for this medicine was built upon pivotal trials that met regulatory standards, as well as data from historical clinical studies. Research examined conditions presenting with cycles of stability and flare-ups. These trials examined the acute inflammatory response, measured by monitoring physiological strain and changes in visible signs like tissue swelling and redness. The evidence contributes to the broader evidence landscape related to acute inflammatory processes in the eye.

Long-Term Evidence and Observation Durations

Studies focusing on Presacor were designed to explore short-term symptom changes, primarily for acute needs. Research so far indicates that the follow-up durations were limited, mainly focusing on the acute phases of the conditions studied. This means there is limited information for long-term outcomes that would provide context on the recurrence of symptoms or the durability of effect beyond the defined treatment window.

Evidence in Specific Patient Populations

Research describes that this medicine was evaluated in a variety of patient groups. Data show patterns related to use across geriatric populations, where data show patterns observed in younger adults. Research also describes that the medicine was evaluated in certain pediatric populations. However, these findings are often supported by the extrapolation of data from adult trials, and research indicates that specific data for some pediatric subgroups remain insufficient.

What is Still Uncertain About Presacor's Research

Several limitations and uncertainties exist in the current research base. The findings from different trials were mixed regarding specific endpoints, such as the rate of inflammation clearance, suggesting that certainty remains low regarding the consistency of measured outcomes. Long-term effects are not fully established because follow-up durations were limited across the majority of the studies. There is also limited information for long-term outcomes regarding the necessity and duration of safety monitoring when the compound is used for extended periods.

Frequently Asked Questions (FAQ)

Common questions about Presacor (FAQ)


Q: Is Presacor considered a long-term medication?

A: Official product information emphasizes that this type of steroid medicine is not intended for long-term use. Prolonged administration can increase certain risks, such as the development of glaucoma or cataracts. Regulatory warnings and research limitations suggest that use is generally intended for acute or short-term needs, rather than long-term chronic treatment.

Q: What is the difference between Presacor and [similar common drug name]?

A: Presacor is a specialized medication formulated as an ophthalmic suspension, meaning it is specifically designed as an eye drop for topical use in the eye. This localized delivery minimizes systemic absorption and distinguishes it from similar medicines that are taken orally (by mouth) for effects throughout the body.

Q: Can I take Presacor if I also take over-the-counter pain relievers?

A: Regulatory labels for this ophthalmic product generally do not list specific oral pain relievers as strict contraindications. Regulatory guidelines emphasize the importance of informing the healthcare professional of all concomitant medications, including OTC pain relievers, before use due to the theoretical potential for minimal systemic absorption.

Q: Is Presacor available in different strengths or forms?

A: The active ingredient, Prednisolone Acetate Ophthalmic Suspension, is commonly supplied in a 1.0% strength. Depending on the specific brand or generic version, other strengths such as a 0.12% concentration may also be available in the ophthalmic suspension or solution form.

Q: Does Presacor interact with common cold or flu medicines?

A: While cold and flu medicines are not specifically named on the product label, some contain ingredients that can affect how the body processes medications. General professional standards recommend disclosing all current medications to the healthcare provider, as some ingredients in cold and flu products can potentially influence the overall concentration of Presacor's active compound.

Q: Are there any known interactions between Presacor and herbal teas?

A: The official product label specifically names the herbal product St. John's Wort as a potential interacting substance that may reduce the medicine's effectiveness. No other common herbal teas are typically addressed in the regulatory documentation for this product.

Q: How quickly do the effects of Presacor usually start?

A: Official product labeling does not provide a precise timeline for therapeutic effects. Studies focusing on the drug's concentration in the eye indicate that the active compound begins to penetrate the ocular tissue and reach substantial concentrations within minutes of being administered as an eye drop.

Q: Does Presacor cause any noticeable feeling when it starts working?

A: Common effects immediately following the application of the eye drop include temporary mild sensations such as stinging, burning, or irritation. Official information indicates that if irritation or the original inflammatory symptoms worsen or persist, patients should be in contact with their healthcare professional.

Q: What happens if I stop taking Presacor suddenly?

A: Stopping any corticosteroid suddenly is generally not recommended, particularly after frequent use for an extended period. The steroid class carries the risk of adrenal suppression, where the body's natural hormone production may be temporarily reduced. Official product information suggests that any adjustments to the treatment schedule, including discontinuation, are typically managed by a healthcare professional.

Q: Why is Presacor sometimes described as a 'cardiovascular' drug?

A: Presacor is categorized as an ophthalmic corticosteroid, not a primary cardiovascular drug. However, official safety warnings mention that systemically absorbed steroids can lead to effects like fluid retention and elevated blood pressure. These are potential adverse reactions that are monitored by a physician.

Q: Is Presacor safe for people with kidney problems?

A: Regulatory labels do not generally list pre-existing kidney conditions as an absolute prohibition for use. However, the systemic absorption of the steroid class can sometimes lead to fluid and electrolyte imbalance, such as hypokalemia. Patients with pre-existing kidney conditions may require medical monitoring, as the steroid class can potentially complicate conditions involving fluid and electrolyte balance.

Q: Do I need to avoid alcohol completely while on Presacor?

A: The official product information for the ophthalmic suspension does not typically list alcohol as a specific substance that must be strictly avoided. This is due to the minimal expected systemic absorption when the eye drops are used correctly.

Q: Is Presacor widely researched, and where can I find the studies?

A: The active ingredient, Prednisolone, is supported by extensive research used to meet regulatory approval standards. Summaries of this evidence can be found on government health websites like DailyMed and MedlinePlus. Information on the trials themselves is registered on sites like ClinicalTrials.gov.

Q: Can Presacor affect my ability to drive or operate machinery?

A: The official patient information advises that the application of the eye drops may cause temporary blurred vision. Due to the potential for temporary blurred vision, official information states that activities requiring clear vision, such as driving or operating machinery, should be avoided until vision has fully cleared.

Q: Are headaches a common side effect of Presacor?

A: Headaches are not typically listed among the most frequent adverse reactions reported in clinical trial summaries for the ophthalmic suspension. Regulatory processes require that all adverse events, including less common ones, are documented and can be reported to a healthcare professional or regulatory body.

Q: Is there a generic version of Presacor available?

A: The active ingredient, Prednisolone Acetate Ophthalmic Suspension, is widely available under various brand names and as authorized generic equivalents in the United States and other international markets. Generic status is governed by regulatory lists like the FDA's Orange Book.

Q: How long does Presacor stay in your system?

A: The drug's half-life in the local ocular tissue is relatively short, often measured in minutes. Due to the targeted topical application of the eye drops, the amount of medicine that enters the bloodstream is minimal, meaning systemic effects are rare and its clearance from the body is generally rapid.

Q: What should I know about Presacor before a planned surgery?

A: Patients should be aware that the use of ocular steroids after surgery, such as cataract removal, has been linked to the potential to delay wound healing. It is essential to inform the surgical team and healthcare provider of its use.

Q: Is it normal to feel a change in heart rate when starting Presacor?

A: Changes in heart rate are not a commonly reported adverse reaction for this ophthalmic product. While systemic steroid use can potentially affect electrolyte balance, which in turn influences heart rhythm, this is considered a rare event with correct topical application.

Q: What does the FDA / EMA classification say about Presacor's safety profile?

A: The drug is classified as a Prescription Drug (Rx) by regulatory authorities. The FDA has historically placed it in Pregnancy Category C, which means it should only be used during pregnancy if the potential benefit to the mother justifies the potential risk to the fetus.

Q: Does Presacor interact with grapefruit?

A: The official product label does not specifically name grapefruit. However, grapefruit juice is a known inhibitor of the CYP3A4 enzyme, which is responsible for metabolizing the steroid compound. This type of interaction could theoretically increase drug exposure if significant systemic absorption were to occur.

Q: Is it normal to have mild stomach upset when first taking Presacor?

A: General gastrointestinal issues like mild stomach upset or nausea are not listed as common or frequent side effects of the ophthalmic product. Such effects are more typically associated with the systemic use of corticosteroids.

Q: Who is the manufacturer of Presacor?

A: As a general drug compound, the active ingredient, Prednisolone Acetate, is supplied by multiple pharmaceutical companies. The specific manufacturer of the 'Presacor' brand name varies by regulatory region and country, and this information is available on the product labeling.

Q: What is the purpose of the black box warning on Presacor, if any?

A: Official FDA labeling for Prednisolone Acetate ophthalmic suspension does not include a Black Box Warning. While the label contains serious warnings about risks like glaucoma, cataracts, and secondary infection, these are presented in the general warnings section rather than the most severe 'Black Box' format.

Q: How often are the safety guidelines for Presacor reviewed?

A: Regulatory bodies like the FDA and EMA maintain a process of continuous review for all prescription medication labels. Safety guidelines are updated and revised whenever new, clinically significant safety information becomes available to ensure the labels reflect the most current authoritative data.

Q: What kind of specialist usually prescribes Presacor?

A: Since this is a specialized ophthalmic suspension, the initial prescription is often provided by a physician who specializes in eye care. This is typically an Ophthalmologist, who can monitor the patient's eye health and intraocular pressure using specialized equipment.

Q: What is the legal status of Presacor (prescription vs. OTC)?

A: Presacor is classified as a Prescription Drug (Rx) by regulatory authorities in all regions. It is not available for purchase without a valid prescription from a licensed healthcare provider.

Q: Does Presacor affect cholesterol levels?

A: Official product labeling does not typically list direct effects on cholesterol levels. However, the systemic use of corticosteroids is known to influence various Endocrine and Metabolic markers, which may warrant general monitoring during use.

How should Presacor be stored and disposed of?

How to Store and Dispose of Presacor?

Presacor (Prednisolone Acetate ophthalmic suspension) must be stored strictly according to regulatory labeling to maintain sterility and potency.


Storage and Stability

The medication requires storage at Controlled Room Temperature, typically 15 C to 30 C. It is mandatory to protect from freezing and store the bottle in an upright position, kept tightly closed to avoid moisture and light. The product must be stored out of the sight and reach of children.

For stability, the suspension must be discarded four weeks (28 days) after the first opening.


Disposal

Unused or expired Presacor must be disposed of in accordance with local pharmaceutical waste guidelines. Consult a healthcare professional or a local drug take-back program for proper disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Presacor found in:

A-Z Index: